Logo image
Use of acetazolamide to decrease cerebrospinal fluid production in chronically ventilated patients with ventriculopleural shunts
Journal article   Open access   Peer reviewed

Use of acetazolamide to decrease cerebrospinal fluid production in chronically ventilated patients with ventriculopleural shunts

E. Carrion, J.H. Hertzog, M.D. Medlock, G.J. Hauser and H.J. Dalton
Archives of Disease in Childhood, Vol.84(1)
2001

Abstract

Acetazolamide Carbonic Anhydrase Inhibitors Cerebrospinal Fluid Cerebrospinal Fluid Shunts Fatal Outcome Female Follow-Up Studies Humans Hydrocephalus Infant Infant, Newborn Male Respiration, Artificial Treatment Failure acetazolamide bicarbonate carbonate dehydratase inhibitor potassium anastomosis article artificial ventilation brain ventricle peritoneum shunt case report cerebrospinal fluid pressure child female human hydrocephalus male priority journal treatment indication
Acetazolamide (ACTZ), a carbonic anhydrase inhibitor, has been shown to decrease cerebrospinal fluid (CSF) production in both in vivo and in vitro animal models. We report two children with hydrocephalus who experienced multiple shunt failures, and who had externalised ventriculostomy drains (EVD) prior to ventriculopleural shunt placement. The effects of increasing doses of ACTZ on CSF production and subsequent tolerance to ventriculopleural shunts were evaluated. The patients had a 48% and a 39% decrease in their EVD CSF output when compared to baseline with maximum ACTZ dose of 75 mg/kg/day and 50 mg/kg/day, respectively (p < 0.05). This is the first report of change in CSF volume in children after extended treatment with ACTZ. ACTZ treatment in mechanically ventilated paediatric patients with hydrocephalus may improve tolerance of ventriculopleural shunts and minimise respiratory compromise. Potassium and bicarbonate supplements are required to correct metabolic disturbances.
url
https://doi.org/10.1136/adc.84.1.68View
Published (Version of record) Open

Metrics

5 Record Views

Details

Logo image